nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Etoposide—muscle cancer	0.746	1	CbGbCtD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—TP63—muscle cancer	0.0446	0.292	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—PAX3—muscle cancer	0.0324	0.213	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—DMD—muscle cancer	0.0206	0.135	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TP73—muscle cancer	0.0199	0.13	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—muscle cancer	0.0131	0.0861	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—MDM2—muscle cancer	0.0127	0.0835	CbGpPWpGaD
Dolutegravir—Bilirubin total increased—Doxorubicin—muscle cancer	0.00574	0.0566	CcSEcCtD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.00417	0.0273	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.0037	0.0243	CbGpPWpGaD
Dolutegravir—Opportunistic infection—Methotrexate—muscle cancer	0.0033	0.0326	CcSEcCtD
Dolutegravir—Opportunistic infection—Doxorubicin—muscle cancer	0.00286	0.0282	CcSEcCtD
Dolutegravir—Myositis—Doxorubicin—muscle cancer	0.00235	0.0232	CcSEcCtD
Dolutegravir—Inflammation—Etoposide—muscle cancer	0.00229	0.0226	CcSEcCtD
Dolutegravir—Rash maculo-papular—Etoposide—muscle cancer	0.00202	0.0199	CcSEcCtD
Dolutegravir—Serum creatinine increased—Doxorubicin—muscle cancer	0.00187	0.0185	CcSEcCtD
Dolutegravir—Neutropenia—Dactinomycin—muscle cancer	0.0018	0.0178	CcSEcCtD
Dolutegravir—Neutropenia—Vincristine—muscle cancer	0.00161	0.0159	CcSEcCtD
Dolutegravir—Hepatitis—Dactinomycin—muscle cancer	0.00154	0.0152	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00142	0.014	CcSEcCtD
Dolutegravir—Inflammation—Methotrexate—muscle cancer	0.00137	0.0135	CcSEcCtD
Dolutegravir—Urinary tract disorder—Vincristine—muscle cancer	0.00136	0.0134	CcSEcCtD
Dolutegravir—Urethral disorder—Vincristine—muscle cancer	0.00135	0.0133	CcSEcCtD
Dolutegravir—Neutropenia—Etoposide—muscle cancer	0.0013	0.0129	CcSEcCtD
Dolutegravir—Renal failure—Etoposide—muscle cancer	0.00122	0.012	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Doxorubicin—muscle cancer	0.00122	0.012	CcSEcCtD
Dolutegravir—Mental disorder—Vincristine—muscle cancer	0.00121	0.0119	CcSEcCtD
Dolutegravir—Inflammation—Doxorubicin—muscle cancer	0.00119	0.0117	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Etoposide—muscle cancer	0.00118	0.0116	CcSEcCtD
Dolutegravir—Abnormal dreams—Doxorubicin—muscle cancer	0.00114	0.0112	CcSEcCtD
Dolutegravir—Urinary tract disorder—Etoposide—muscle cancer	0.0011	0.0109	CcSEcCtD
Dolutegravir—Urethral disorder—Etoposide—muscle cancer	0.00109	0.0108	CcSEcCtD
Dolutegravir—Vertigo—Vincristine—muscle cancer	0.00108	0.0106	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—muscle cancer	0.00105	0.0103	CcSEcCtD
Dolutegravir—Immune system disorder—Etoposide—muscle cancer	0.00101	0.00994	CcSEcCtD
Dolutegravir—Nervous system disorder—Vincristine—muscle cancer	0.00096	0.00946	CcSEcCtD
Dolutegravir—Fatigue—Dactinomycin—muscle cancer	0.000944	0.00931	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000896	0.00883	CcSEcCtD
Dolutegravir—Insomnia—Vincristine—muscle cancer	0.000885	0.00873	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—muscle cancer	0.000879	0.00867	CcSEcCtD
Dolutegravir—Vertigo—Etoposide—muscle cancer	0.000873	0.0086	CcSEcCtD
Dolutegravir—Abdominal pain—Dactinomycin—muscle cancer	0.000866	0.00854	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Vincristine—muscle cancer	0.000845	0.00833	CcSEcCtD
Dolutegravir—Fatigue—Vincristine—muscle cancer	0.000844	0.00832	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000821	0.0081	CcSEcCtD
Dolutegravir—Hypersensitivity—Dactinomycin—muscle cancer	0.000807	0.00796	CcSEcCtD
Dolutegravir—Abdominal discomfort—Methotrexate—muscle cancer	0.0008	0.00789	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Vincristine—muscle cancer	0.0008	0.00789	CcSEcCtD
Dolutegravir—Asthenia—Dactinomycin—muscle cancer	0.000786	0.00775	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—muscle cancer	0.000784	0.00773	CcSEcCtD
Dolutegravir—Neutropenia—Methotrexate—muscle cancer	0.000781	0.0077	CcSEcCtD
Dolutegravir—Abdominal pain—Vincristine—muscle cancer	0.000773	0.00763	CcSEcCtD
Dolutegravir—Skin disorder—Etoposide—muscle cancer	0.00077	0.00759	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—muscle cancer	0.000764	0.00753	CcSEcCtD
Dolutegravir—Diarrhoea—Dactinomycin—muscle cancer	0.000749	0.00739	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000738	0.00727	CcSEcCtD
Dolutegravir—Renal failure—Methotrexate—muscle cancer	0.000732	0.00722	CcSEcCtD
Dolutegravir—Hypersensitivity—Vincristine—muscle cancer	0.000721	0.00711	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Methotrexate—muscle cancer	0.000704	0.00694	CcSEcCtD
Dolutegravir—Asthenia—Vincristine—muscle cancer	0.000702	0.00692	CcSEcCtD
Dolutegravir—Vomiting—Dactinomycin—muscle cancer	0.000696	0.00687	CcSEcCtD
Dolutegravir—Rash—Dactinomycin—muscle cancer	0.000691	0.00681	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Etoposide—muscle cancer	0.000684	0.00675	CcSEcCtD
Dolutegravir—Fatigue—Etoposide—muscle cancer	0.000683	0.00674	CcSEcCtD
Dolutegravir—Neutropenia—Doxorubicin—muscle cancer	0.000676	0.00667	CcSEcCtD
Dolutegravir—Diarrhoea—Vincristine—muscle cancer	0.000669	0.0066	CcSEcCtD
Dolutegravir—Hepatitis—Methotrexate—muscle cancer	0.000668	0.00659	CcSEcCtD
Dolutegravir—Urinary tract disorder—Methotrexate—muscle cancer	0.00066	0.00651	CcSEcCtD
Dolutegravir—Urethral disorder—Methotrexate—muscle cancer	0.000655	0.00646	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—muscle cancer	0.000652	0.00643	CcSEcCtD
Dolutegravir—Nausea—Dactinomycin—muscle cancer	0.00065	0.00641	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Etoposide—muscle cancer	0.000648	0.00639	CcSEcCtD
Dolutegravir—Dizziness—Vincristine—muscle cancer	0.000647	0.00638	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—muscle cancer	0.000634	0.00625	CcSEcCtD
Dolutegravir—Abdominal pain—Etoposide—muscle cancer	0.000627	0.00618	CcSEcCtD
Dolutegravir—Vomiting—Vincristine—muscle cancer	0.000622	0.00613	CcSEcCtD
Dolutegravir—Rash—Vincristine—muscle cancer	0.000617	0.00608	CcSEcCtD
Dolutegravir—Dermatitis—Vincristine—muscle cancer	0.000616	0.00608	CcSEcCtD
Dolutegravir—Headache—Vincristine—muscle cancer	0.000613	0.00604	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00061	0.00601	CcSEcCtD
Dolutegravir—Immune system disorder—Methotrexate—muscle cancer	0.000604	0.00595	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—FH—muscle cancer	0.000599	0.00393	CbGpPWpGaD
Dolutegravir—Mental disorder—Methotrexate—muscle cancer	0.000585	0.00577	CcSEcCtD
Dolutegravir—Hypersensitivity—Etoposide—muscle cancer	0.000584	0.00576	CcSEcCtD
Dolutegravir—Nausea—Vincristine—muscle cancer	0.000581	0.00573	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—muscle cancer	0.000579	0.00571	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—muscle cancer	0.000571	0.00563	CcSEcCtD
Dolutegravir—Asthenia—Etoposide—muscle cancer	0.000569	0.00561	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—muscle cancer	0.000567	0.00559	CcSEcCtD
Dolutegravir—Pruritus—Etoposide—muscle cancer	0.000561	0.00553	CcSEcCtD
Dolutegravir—Diarrhoea—Etoposide—muscle cancer	0.000542	0.00535	CcSEcCtD
Dolutegravir—Dizziness—Etoposide—muscle cancer	0.000524	0.00517	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—muscle cancer	0.000523	0.00515	CcSEcCtD
Dolutegravir—Vertigo—Methotrexate—muscle cancer	0.000523	0.00515	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—muscle cancer	0.000507	0.005	CcSEcCtD
Dolutegravir—Vomiting—Etoposide—muscle cancer	0.000504	0.00497	CcSEcCtD
Dolutegravir—Rash—Etoposide—muscle cancer	0.0005	0.00493	CcSEcCtD
Dolutegravir—Dermatitis—Etoposide—muscle cancer	0.000499	0.00492	CcSEcCtD
Dolutegravir—Headache—Etoposide—muscle cancer	0.000497	0.0049	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—muscle cancer	0.000496	0.00489	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000492	0.00485	CcSEcCtD
Dolutegravir—Nausea—Etoposide—muscle cancer	0.000471	0.00464	CcSEcCtD
Dolutegravir—Nervous system disorder—Methotrexate—muscle cancer	0.000466	0.00459	CcSEcCtD
Dolutegravir—Skin disorder—Methotrexate—muscle cancer	0.000461	0.00455	CcSEcCtD
Dolutegravir—Vertigo—Doxorubicin—muscle cancer	0.000453	0.00446	CcSEcCtD
Dolutegravir—Insomnia—Methotrexate—muscle cancer	0.000429	0.00423	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000426	0.0042	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00041	0.00404	CcSEcCtD
Dolutegravir—Fatigue—Methotrexate—muscle cancer	0.000409	0.00404	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—muscle cancer	0.000403	0.00398	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—muscle cancer	0.000399	0.00394	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Methotrexate—muscle cancer	0.000388	0.00383	CcSEcCtD
Dolutegravir—Abdominal pain—Methotrexate—muscle cancer	0.000375	0.0037	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—muscle cancer	0.000372	0.00367	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000355	0.0035	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—muscle cancer	0.000354	0.00349	CcSEcCtD
Dolutegravir—Hypersensitivity—Methotrexate—muscle cancer	0.00035	0.00345	CcSEcCtD
Dolutegravir—Asthenia—Methotrexate—muscle cancer	0.000341	0.00336	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—MED12—muscle cancer	0.000338	0.00222	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000336	0.00331	CcSEcCtD
Dolutegravir—Pruritus—Methotrexate—muscle cancer	0.000336	0.00331	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—muscle cancer	0.000325	0.0032	CcSEcCtD
Dolutegravir—Diarrhoea—Methotrexate—muscle cancer	0.000325	0.0032	CcSEcCtD
Dolutegravir—Dizziness—Methotrexate—muscle cancer	0.000314	0.0031	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ENO2—muscle cancer	0.000309	0.00202	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Doxorubicin—muscle cancer	0.000303	0.00299	CcSEcCtD
Dolutegravir—Vomiting—Methotrexate—muscle cancer	0.000302	0.00298	CcSEcCtD
Dolutegravir—Rash—Methotrexate—muscle cancer	0.000299	0.00295	CcSEcCtD
Dolutegravir—Dermatitis—Methotrexate—muscle cancer	0.000299	0.00295	CcSEcCtD
Dolutegravir—Headache—Methotrexate—muscle cancer	0.000297	0.00293	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—muscle cancer	0.000295	0.00291	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—muscle cancer	0.000291	0.00287	CcSEcCtD
Dolutegravir—Nausea—Methotrexate—muscle cancer	0.000282	0.00278	CcSEcCtD
Dolutegravir—Diarrhoea—Doxorubicin—muscle cancer	0.000281	0.00277	CcSEcCtD
Dolutegravir—Dizziness—Doxorubicin—muscle cancer	0.000272	0.00268	CcSEcCtD
Dolutegravir—Vomiting—Doxorubicin—muscle cancer	0.000261	0.00258	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—muscle cancer	0.000259	0.00256	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—muscle cancer	0.000259	0.00255	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—muscle cancer	0.000258	0.00254	CcSEcCtD
Dolutegravir—Nausea—Doxorubicin—muscle cancer	0.000244	0.00241	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—PTGS2—muscle cancer	0.000107	0.000704	CbGpPWpGaD
